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Abstract Coding region and intronic mutations in the gene for
microtubule-associated protein tau cause frontotemporal demen-
tia and Parkinsonism linked to chromosome 17 (FTDP-17).
Most coding region mutations effect a reduced ability of tau
protein to interact with microtubules and lead to the formation of
a filamentous pathology made of hyperphosphorylated tau. Here
we show that trimethylamine N-oxide (TMAO) restores the
ability of tau with FTDP-17 mutations to promote microtubule
assembly. To mimic phosphorylation, serine and threonine
residues in tau were singly or multiply mutated to glutamic acid,
resulting in a reduced ability of tau to promote microtubule
assembly. With the exception of the most heavily substituted
protein (27 glutamic acid residues), TMAO increased the ability
of mutant tau to promote microtubule assembly. However, it had
no significant effect on heparin-induced assembly of tau into
filaments. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The discovery of mutations in the gene for microtubule-
associated protein tau in frontotemporal dementia and Par-
kinsonism linked to chromosome 17 (FTDP-17) has shown
that dysfunction of tau protein is su⁄cient to cause neuro-
degeneration and dementia [1^4]. Known tau mutations are
intronic mutations located close to the splice-donor site of the
intron following exon 10, and missense, deletion or silent mu-
tations in the coding region. A ¢lamentous pathology made of
hyperphosphorylated tau protein is an invariant neuropatho-
logical characteristic of FTDP-17 [5].
Six tau isoforms are produced in the adult human brain by
alternative mRNA splicing from a single gene [6]. They di¡er
from each other by the presence or absence of 29 or 58 amino
acid inserts located in the amino-terminal half and an addi-
tional 31 amino acid repeat located in the carboxy-terminal
half. Inclusion of the latter, which is encoded by exon 10 of
the tau gene, gives rise to the three isoforms with four repeats
each; the other three isoforms have three repeats each. Similar
levels of three-repeat and four-repeat tau isoforms are present
in normal adult human brain [7]. The repeats and some ad-
joining sequences constitute the microtubule-binding domains
of tau [8].
The primary e¡ect of the intronic and some coding region
mutations in exon 10 is at the mRNA level [2^4,9^11]. This
results in a change in the ratio of three- to four-repeat tau
isoforms and the net overproduction of four-repeat tau. By
contrast, most coding region mutations reduce the ability of
mutant tau protein to interact with microtubules [12^18] and
some of these mutations also stimulate the in vitro assembly
of tau into ¢laments [19^21]. The reduced ability of tau to
interact with microtubules probably leads to its hyperphos-
phorylation. This exacerbates the functional de¢cit, since hy-
perphosphorylated tau is known to be unable to bind to mi-
crotubules or to promote microtubule assembly [4].
Recent studies have shown that the organic osmolytes tri-
methylamine N-oxide (TMAO) and betaine increase tau-pro-
moted assembly of microtubules [22] and restore the ability of
tau phosphorylated by cAMP-dependent protein kinase or
glycogen synthase kinase-3L to promote microtubule assembly
[23]. Here, we have investigated the e¡ects of TMAO on the
ability of tau protein with FTDP-17 mutations to promote
microtubule assembly. In addition, we have introduced gluta-
mic acid in place of serine and threonine residues, most of
which are phosphorylated in pathological tau, to mimic phos-
phorylation. The ability of these glutamate mutant tau pro-
teins to promote microtubule assembly in the presence and
absence of TMAO was also investigated.
2. Materials and methods
2.1. Expression and puri¢cation of wild-type and mutated tau proteins
Site-directed mutagenesis was used to change K257 to threonine or
glutamic acid, G272 to valine, to delete K280, to change P301 to
leucine, serine or glutamic acid and to change V337 to methionine
in the four-repeat 412 amino acid isoform of human tau (expressed
from cDNA clone tau46) (in the numbering of the 441 amino acid
isoform of human tau). In addition, S235, S262, S356 and S396 were
separately changed to glutamic acid in the four-repeat 441 amino acid
isoform of human tau (expressed from cDNA clone tau40), to mimic
phosphorylation at single sites. Three additional constructs (called
Etau8, Etau18 and Etau27) were produced using polymerase chain
reaction methods, in which multiple serine and threonine residues
were changed to glutamic acid in the 441 amino acid isoform of
human tau. In Etau8, residues downstream of the repeat region
were replaced by glutamic acid. In Etau18, residues upstream of the
repeats were replaced by glutamic acid. Etau27 represents a composite
of Etau8 and Etau18, with the addition of S262E. The mutated res-
idues were: S396, S400, T403, S404, S409, S412, S413 and S422 (for
Etau8); S46, T50, T69, T111, T153, T175, T181, S198, S199, S202,
T205, S208, S210, T212, S214, T217, T231 and S235 (for Etau18);
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S46, T50, T69, T111, T153, T175, T181, S198, S199, S202, T205,
S208, S210, T212, S214, T217, T231, S235, S262, S396, S400, T403,
S404, S409, S412, S413 and S422 (for Etau27). All constructs were
veri¢ed by DNA sequencing and by mass spectrometric determination
of the molecular masses of expressed proteins. Wild-type and mutated
tau proteins were expressed in Escherichia coli BL21(DE3), as de-
scribed [7]. Bacterial pellets were resuspended in 50 mM PIPES,
1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 0.5 Wg/ml leupeptin,
pH 6.8, followed by a 2U1-min sonication on ice using a Kontes
Micro Ultrasonic Disrupter. The homogenates were centrifuged at
27 000Ug for 15 min. Supernatants were loaded onto phosphocellu-
lose columns (bed volume, 2 ml) equilibrated in extraction bu¡er. The
columns were washed in extraction bu¡er, followed by extraction
bu¡er+0.1 M NaCl. The protein was eluted batchwise with 6 ml ex-
traction bu¡er containing 0.3 M NaCl and the eluates passed through
0.2 Wm Acrodisc. This was followed by overnight dialysis against a
saturated ammonium sulphate solution and precipitation by a 10-min
centrifugation at 50 000 rpm (Beckman TL100). The pellets were re-
suspended in extraction bu¡er and reprecipitated by addition of an
equal volume of saturated ammonium sulphate. Following centrifu-
gation, the pellets were resuspended in 1 ml extraction bu¡er contain-
ing 0.5 M NaCl and 2% 2-mercaptoethanol, and held at 100‡C for
5 min. Following a 10-min centrifugation at 50 000 rpm, the super-
natants were loaded onto NAP10 columns equilibrated in 80 mM
PIPES, 1 mM EGTA, 0.2 mM MgCl2, 1 mM DTT (microtubule
assembly bu¡er minus GTP) and eluted with 1.5 ml of the same bu¡-
er. GTP was added to 1 mM. Tau protein concentrations were deter-
mined using densitometry (Molecular Dynamics) of Coomassie blue-
stained polyacrylamide gels and calibration against tau protein of
known concentration. Bovine serum albumin was used as the stan-
dard for densitometry. In all experiments, wild-type and mutant tau
proteins were expressed and puri¢ed in parallel.
2.2. Microtubule assembly
Puri¢ed recombinant wild-type and mutant htau40 and htau46 were
used at 0.1 mg/ml. They were incubated with bovine brain tubulin
(1 mg/ml, 20 WM, Cytoskeleton) in assembly bu¡er at 37‡C, as de-
scribed [12]. TMAO (Sigma Fine Chemicals) or betaine (Sigma Fine
Chemicals) was used at 200 mM. The assembly of tubulin into micro-
tubules was monitored over time by a change in turbidity at 350 nm.
Maximum assembly rate was measured for each turbidity/time plot by
taking the slope of the tangent at the steepest point of the curve and
expressed as A350 nm/min. Relative assembly rates were calculated
from the averages of the maximum rates in the presence or absence
of TMAO.
2.3. Tau ¢lament assembly
Tau proteins were expressed and puri¢ed as described [21]. Puri¢ed
wild-type htau46 and htau46P301S (3 mg/ml) were incubated in the
absence or the presence of various concentrations of heparin (100, 200
and 400 Wg/ml; British Drug House) in 25 Wl of 30 mM MOPS, 1 mM
4-(2-aminoethyl)benzenesulphonyl£uoride (Calbiochem), pH 7.4, at
Fig. 1. Amino acid changes in tau protein whose e¡ects on tau-promoted microtubule assembly were investigated. A: Schematic drawing of the
412 amino acid isoform of human tau (tau46). The four tandem repeats are shown as shaded bars, with the amino-terminal 29 amino acid in-
sert shown in light grey. The positions of FTDP-17 mutations K257T, G272V, vK280, P301L, P301S and V337M are indicated. Amino acid
substitutions K257E and P301E are also shown. All residues were mutated individually. B: Schematic diagram of the 441 amino acid isoform
of human tau (tau40). The repeats are shown as shaded bars, with the two 29 amino acid amino-terminal inserts shown in light and dark grey,
respectively. Amino acid substitutions S235E, S262E, S356E and S396E are indicated. The four residues were mutated individually. C^E: Sche-
matic diagram indicating the positions of eight (C), 18 (D) or 27 (E) S or T to E mutations that were introduced into the 441 amino acid iso-
form of human tau to generate Etau8, Etau18 and Etau27.
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37‡C for up to 48 h, as described [24]. Experiments were carried out in
the presence or absence of 100^800 mM TMAO. Aliquots were taken
at 20 and 48 h, placed onto carbon-coated 400-mesh grids and stained
with 1% lithium phosphotungstate. Micrographs were recorded at a
nominal magni¢cation of U40 000 on a Philips model EM208S elec-
tron microscope. Each ¢lament assembly experiment made use of
freshly prepared batches of recombinant wild-type and mutant tau
proteins that had been puri¢ed in parallel. Three separate assembly
experiments were carried out.
3. Results
The amino acid changes in tau protein whose e¡ects on tau-
promoted microtubule assembly were studied are shown sche-
matically in Fig. 1. Tau proteins with the FTDP-17 mutations
K257T, G272V, vK280, P301L, P301S and V337M [1,2,14,
16,18] showed a reduced ability to promote microtubule as-
sembly, in con¢rmation of our previous results [12,14,16,18]
(Fig. 2). The same was true of tau proteins with arti¢cial
Fig. 2. E¡ects of tau mutations K257T, K257E, G272V, vK280, P301L, P301S, P301E and V337M on the ability of tau to promote microtu-
bule assembly (in bold), as compared with wild-type 412 tau46 (regular). Experiments were carried out in the absence (3) or the presence (+)
of 200 mM TMAO. Polymerisation of tubulin was monitored over time by turbidimetry. A typical experiment is shown; similar results were
obtained using at least three separate preparations of each mutant protein.
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mutations K257E and P301E. When compared with the ef-
fects of the K257T, P301L and P301S mutations, the presence
of glutamic acid at codons 257 and 301 resulted in a much
greater reduction in the ability of tau to promote microtubule
assembly (Fig. 2). When 200 mM TMAO was included in the
assembly mixture containing tau and tubulin, the rate and
extent of the increase in turbidity given by the tau mutants
were equivalent or greater than those seen with wild-type tau
in the absence of TMAO (Fig. 2). In the presence of TMAO,
wild-type tau also assembled at a faster rate and to a greater
extent, in con¢rmation of previous ¢ndings [22,23] (Fig. 2).
The relative maximum rate for assembly in the presence and
absence of TMAO was 2.7 for wild-type htau46 and ranged
between 4.6 and 47 for the mutants examined. Similar results
were obtained using betaine instead of TMAO (not shown).
To mimic the e¡ects of phosphorylation, we separately re-
placed serine residues 235, 262, 356 or 396 with glutamic acid.
A reduced ability to promote microtubule assembly was ob-
served for each of the mutant tau proteins (Fig. 3). It was
particularly pronounced for tau with the S262E and S356E
mutations, with smaller e¡ects for tau with the S235E and
S396E mutations. In the presence of TMAO, tau proteins
with the S262E and S356E mutations promoted microtubule
assembly at a similar or faster rate than wild-type four-repeat
tau (Fig. 3). Tau proteins with the S235E and S396E muta-
tions were better at promoting microtubule assembly in the
presence of TMAO than wild-type tau in the absence of the
osmolyte. The relative maximum rate for assembly in the
presence and absence of TMAO was 1.7 for wild-type
htau40. It was 6.3 for S235Etau40, 24 for S262Etau40, 144
for S356Etau40 and 3.5 for S396Etau40. No microtubule as-
sembly was observed when tubulin and 200 mM TMAO were
incubated in the absence of tau (data not shown).
Tau proteins were produced in which 8, 18 or 27 glutamic
acid residues replaced serines and threonines (Etau8, Etau18,
Etau27). Many of these residues are phosphorylated in patho-
logical tau. Etau8, Etau18 and Etau27 showed a greatly re-
duced ability to promote microtubule assembly (Fig. 4). How-
ever, in the presence of TMAO, Etau8 promoted microtubule
assembly to a greater extent than wild-type tau. TMAO only
had a small e¡ect on the ability of Etau18 to promote micro-
tubule assembly, with no e¡ect on Etau27 (Fig. 4).
The e¡ect of TMAO on the heparin-induced assembly of
tau into ¢laments was investigated by electron microscopy
using wild-type htau46 and htau46 with the P301S mutation.
No signi¢cant e¡ect of TMAO (100, 200, 400 or 800 mM) was
observed on either the rate of assembly or the number of
¢laments after 48 h.
4. Discussion
Most coding region mutations in Tau associated with
Fig. 3. E¡ects of tau mutations S235E, S262E, S356E and S396E on the ability of tau protein to promote microtubule assembly (in bold), as
compared with wild-type tau40 (regular). Experiments were carried out in the absence (3) or the presence (+) of 200 mM TMAO. Polymerisa-
tion of tubulin was monitored over time by turbidimetry. A typical experiment is shown; similar results were obtained using at least three sepa-
rate preparations of each mutant protein.
Fig. 4. E¡ects of constructs Etau8 (S396E, S400E, T403E, S404E,
S409E, S412E, S413E, S422E), Etau18 (S46E, T50E, T69E, T111E,
T153E, T175E, T181E, S198E, S199E, S202E, T205E, S208E,
S210E, T212E, S214E, T217E, T231E, S235E) and Etau27 (muta-
tions of Etau8+Etau18+S262E) on the promotion of microtubule
assembly (in bold), as compared with wild-type htau46 (regular).
Experiments were carried out in the absence (3) and the presence
(+) of 200 mM TMAO. Polymerisation of tubulin was monitored
over time by turbidimetry. A typical experiment is shown; similar
results were obtained using at least three separate preparations of
each mutant protein.
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FTDP-17 reduce the ability of tau protein to promote micro-
tubule assembly [12^18]. This is believed to be their primary
e¡ect. Here we show that the naturally occurring osmolyte
TMAO is able to overcome the functional de¢cit caused by
these mutations.
In the presence of 200 mM TMAO, recombinant tau pro-
teins with six di¡erent coding region mutations (K257T,
G272V, vK280, P301L, P301S or V337M) promoted micro-
tubule assembly at a faster rate and to a more signi¢cant
extent than wild-type tau. Of the known mutations in Tau,
K257T and P301S create potential new phosphorylation sites.
To mimic phosphorylation, we produced K257E and P301E
recombinant four-repeat tau. Both proteins were much poorer
at promoting microtubule assembly than tau proteins with the
K257T or P301S mutations, indicating that phosphorylation
of T257 and S301 in FTDP-17 brain could signi¢cantly exac-
erbate the primary e¡ects of these missense mutations. In the
presence of 200 mM TMAO, K257Etau46 and P301Etau46
promoted microtubule assembly to wild-type levels.
In all diseases with tau pathology, whether sporadic or
familial, ¢lamentous tau is abnormally hyperphosphorylated
[4,5]. Many studies have helped to identify phosphorylation
sites, as well as protein kinases and protein phosphatases that
may be involved. In order to mimic the e¡ects of phosphor-
ylation, we mutated serine and threonine residues, either sin-
gly or multiply, to glutamic acid. Of the four singly mutated
sites (S235E, S262E, S356E and S396E), tau protein with the
S356E mutation showed a greatly reduced ability to promote
microtubule assembly. A large e¡ect was also observed for
tau40 with the S262E mutation, with smaller e¡ects resulting
from mutations S235E and S396E. In the presence of 200 mM
TMAO, the mutant tau proteins behaved like wild-type four-
repeat tau in their ability to promote microtubule assembly.
These results are in line with ¢ndings showing that phosphor-
ylation of the KIGS motifs in the repeat region leads to a
marked reduction in the ability of tau to interact with micro-
tubules [25,26]. Phosphorylation of S262 and S356 in tau ap-
pears to play a major part in regulating its ability to interact
with microtubules.
However, phosphorylation at these sites in ¢lamentous tau
is variable. Although S262 and S356 are phosphorylated to
some extent in ¢lamentous tau in Alzheimer’s disease brain
[27,28], they are not phosphorylated in Pick bodies in Pick’s
disease [29] or in the Pick body-like inclusions in cases of
FTDP-17 with mutations K257T and G272V in tau [18,30].
This contrasts with S235 and S396 which are phosphorylated
in all the known ¢lamentous tau deposits [4]. Tau protein with
the S235E or S396E mutations showed a somewhat reduced
ability to promote microtubule assembly.
In the tauopathies, numerous serine and threonine residues
are hyperphosphorylated [4]. We therefore produced Etau8,
Etau18 and Etau27. In Etau8, mutations were located down-
stream of the repeats, in the carboxy-terminal region of tau.
Etau8 was still able to promote microtubule assembly, albeit
ine⁄ciently, with TMAO restoring it to full activity. Etau18,
with mutations in the amino-terminal half of tau, was greatly
impaired in its ability to promote microtubule assembly.
TMAO was able to increase that ability, but not to control
levels. Etau27 contained S262E, together with the combined
Etau8 and Etau18 mutations. It was totally unable to promote
microtubule assembly, either in the presence or the absence of
200 mM TMAO. These ¢ndings are consistent with the fact
that hyperphosphorylated tau protein from Alzheimer’s dis-
ease brain is unable to promote microtubule assembly [4].
They suggest that TMAO would not be able to overcome
the functional de¢cit caused by hyperphosphorylation of ¢la-
mentous tau. In a recent study, a tau mutant with 10 glutamic
acid residues instead of serines was produced [31]. It was still
able to bind to taxol-stabilised microtubules, but was unable
to interact with the membrane cortex. Based on the present
¢ndings, it appears probable that this Etau10 mutant would
show a greatly reduced ability to promote microtubule assem-
bly.
TMAO can force thermodynamically unfolded proteins to
fold by causing a preferential hydration of exposed polypep-
tide backbone and side chains [32^34]. It has been found to
raise the free energy of the unfolded state of proteins and to
promote folding by a solvophobic e¡ect. Previous studies have
shown that organic osmolytes inhibit the conversion of the
cellular prion protein to the protease-resistant form associated
with transmissible spongiform encephalopathies [35,36]. This
potential protective e¡ect in prion diseases contrasts with the
¢bril-enhancing e¡ect of TMAO on the L-amyloid protein
(AL) associated with Alzheimer’s disease [37].
Tau is a highly £exible, extended molecule with little sec-
ondary structure [21,38,39]. By circular dichroism spectrosco-
py, it appears as a random coil [38], even when carrying
FTDP-17 mutations [21] or in the presence of TMAO [22].
Binding of tau to microtubules generates some ordered struc-
tures, indicating that microtubules can induce conformational
changes in tau [40]. TMAO probably induces a tubulin and/or
tau conformational change that favours tubulin assembly. The
FTDP-17 missense and deletion mutations, as well as the glu-
tamic acid mutations, appear to change the conformation of
tau in such a way that it is less able to interact with micro-
tubules. TMAO overcomes this e¡ect, presumably by promot-
ing the tubulin-induced folding of tau. The FTDP-17 muta-
tions that reduce the ability of tau to interact with
microtubules will favour assembly into ¢laments, because
they increase the proportion of unfolded or partially folded
conformations. This is reminiscent of the mechanism believed
to underlie the assembly of other amyloidogenic proteins
[41,42]. Hyperphosphorylation of tau is likely to exacerbate
this process.
Unlike its e¡ects on microtubule assembly, TMAO did not
in£uence heparin-induced assembly of tau into ¢laments. It
suggests that distinct conformations are involved in physio-
logical tau folding and pathological tau aggregation. This is
borne out by ¢ndings showing that known missense and dele-
tion mutations reduce the ability of tau to promote micro-
tubule assembly [12^18], whereas some of the same mutations
increase heparin-induced assembly of tau into ¢laments [19^
21]. The accelerated formation of tau assemblies from un-
folded protein is probably a second mechanism underlying
the formation of tau pathology in FTDP-17.
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